文献速递其他结缔组织病

可溶性PD-1与PD-L2在系统性硬化症疾病严重程度及进展中的作用

Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2017-08-01

该研究检测了91例系统性硬化症(SSc)患者血清sPD-1和sPD-L2水平,发现两者升高且与纤维化程度和免疫异常相关。SSc患者T细胞、B细胞和巨噬细胞上PD-1和PD-L2表达显著升高。PD-L2高表达B细胞产生更高水平IL-10,提示PD-L2通过T-B细胞同源相互作用调节T细胞细胞因子产生。在拓扑异构酶I诱导的SSc小鼠模型中,腹腔注射重组PD-1-Fc和PD-L2-Fc可取消拓扑异构酶I特异性B细胞的增强IL-10产生效应。

要点

  • SSc患者血清sPD-1和sPD-L2水平升高,与纤维化范围和免疫学异常相关。
  • SSc患者T细胞、B细胞和巨噬细胞上PD-1和PD-L2表达显著升高。
  • PD-L2高表达B细胞产生更高IL-10,PD-1-Fc和PD-L2-Fc可取消小鼠模型中的增强效应。

核心结论

  • sPD-1和sPD-L2通过调节T细胞与B细胞的同源相互作用参与SSc疾病发生发展。

研究设计与样本

  • 研究纳入91例SSc患者,采用ELISA检测血清sPD-1和sPD-L2水平,流式细胞术量化T细胞、B细胞和巨噬细胞上PD-1和PD-L2表达。
  • 采用微流控ELISA(micro-ELISA)分析PD-L2高表达与低表达B细胞的IL-10产生。
  • 在拓扑异构酶I诱导的SSc小鼠模型中评估sPD-1和sPD-L2对疾病进展的影响。

主要发现

  • SSc患者血清sPD-1和sPD-L2水平升高,且与纤维化程度和免疫学异常相关。
  • SSc患者T细胞、B细胞和巨噬细胞上PD-1和PD-L2表达显著升高。
  • PD-L2高表达B细胞较PD-L2低表达B细胞产生更高水平IL-10。
  • 在拓扑异构酶I诱导的SSc小鼠中,拓扑异构酶I特异性B细胞与T细胞及拓扑异构酶I蛋白共培养时IL-10产生显著高于常规B细胞。
  • 腹腔注射重组嵌合PD-1-Fc和PD-L2-Fc可取消上述增强效应。

临床怎么用

  • sPD-1和sPD-L2可能作为评估SSc疾病严重程度和进展的生物标志物。
  • 靶向PD-1/PD-L2通路可能为SSc提供潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the function and serum levels of soluble forms of programmed death 1 (sPD-1) and one of its ligands, soluble PD ligand 2 (sPD-L2), in patients with systemic sclerosis (SSc) and in a mouse model of topoisomerase I (topo I)-induced SSc. METHODS: Serum levels of sPD-1 and sPD-L2 in 91 patients with SSc were examined by enzyme-linked immunosorbent assay (ELISA). Expression of PD-1 and PD-L2 on T cells, B cells, and macrophages was quantified by flow cytometry. The effects of blockade of PD-1 and PD-L2 were analyzed by microfluidic ELISA (micro-ELISA), a technique that can measure very low amounts of cytokines. In addition, the effects of sPD-1 and sPD-L2 on disease progression were assessed in mice with topo I-induced SSc. RESULTS: Serum levels of sPD-1 and sPD-L2 were elevated in patients with SSc and correlated with the extent of fibrosis and immunologic abnormalities. Expression levels of PD-1 and PD-L2 were significantly elevated on SSc T cells, B cells, and macrophages. Micro-ELISA analysis of serum samples from patients with SSc showed that PD-L2high B cells had higher levels of interleukin-10 (IL-10) production compared with PD-L2low B cells, indicating that PD-L2 acts as a regulator of T cell cytokine production via cognate interactions with T cells and B cells. In mice with topo I-induced SSc, production of IL-10 by topo I-specific B cells in cultures with T cells and topo I protein was significantly higher than that by conventional B cells, and intraperitoneal injection of recombinant chimeric PD-1-Fc and PD-L2-Fc canceled these enhanced effects. CONCLUSION: These results suggest that sPD-1 and sPD-L2 contribute to disease development in SSc via the regulation of cognate interactions with T cells and B cells.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fukasawa T, Yoshizaki A, Ebata S, et al. Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis. Arthritis Rheumatol. 2017. PMID: 28556548. doi:10.1002/art.40164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。